The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Insulin and Insulin-like Growth Factor-1 Regulate Tau Phosphorylation in Cultured Human Neurons
Open accessAbstract
Hyperphosphorylated tau is the major component of paired helical filaments in neurofibrillary lesions associated with Alzheimer's disease. Hyperphosphorylation reduces the affinity of tau for microtubules and is thought to be a critical event in the pathogenesis of this disease. Recently, glycogen-synthase kinase-3 has been shown to phosphorylate tau in vitro and in non-neuronal cells transfected with tau. The activity of glycogen-synthase kinase-3 can be down-regulated in response to insulin or insulin-like growth factor-1 through the activation of the phosphatidylinositol 3-kinase pathway. We therefore hypothesize that insulin or insulin-like growth factor-1 may affect tau phosphorylation through the inhibition of glycogen-synthase kinase-3 in neurons. Using cultured human neuronal NT2N cells, we demonstrate that glycogen-synthase kinase-3 phosphorylates tau and reduces its affinity for microtubules and that insulin and insulin-like growth factor-1 stimulation reduces tau phosphorylation and promotes tau binding to microtubules. We further demonstrate that these effects of insulin and insulin-like growth factor-1 are mediated through the inhibition of glycogen-synthase kinase-3 via the phosphatidylinositol 3-kinase/protein kinase B signaling pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
A protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Regulation of neuronal survival by the serine-threonine protein kinase Akt
Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., & Greenberg, M. E. (1997) · Science · doi:10.1126/science.275.5300.661 · Cited by 2,436
The distribution of tau in the mammalian central nervous system.
Binder, L. I., Frankfurter, A., & Rebhun, L. I. (1985) · The Journal of cell biology · doi:10.1083/jcb.101.4.1371 · Cited by 1,588
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418
Self-citation
Cited by
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Self-citationSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703
“Moreover, the increased levels of phosphotau that are generally detected in AD brains could reflect impaired insulin/IGF-I signaling with attendant increased levels of GSK-3 β activity, since GSK-3β is one of the major kinases responsible for hyper-phosphorylating tau [46].”
BackgroundDiabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258
“Insulin has also been hypothesized to regulate phosphorylation.(37,38) Finally, other potential mechanisms include the production of advanced glycation end products(39) or alterations of oxidative stress pathways, calcium homeostasis, and hippocampal synaptic plasticity.”
BackgroundPI3K/Akt and apoptosis: size matters
Franke, T. F., Hornik, C. P., Segev, L., Shostak, G. A., & Sugimoto, C. (2003) · Oncogene · doi:10.1038/sj.onc.1207115 · Cited by 1,184
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158
Thorne, R. G., Pronk, G. J., Padmanabhan, V., & Frey, W. H. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.029 · Cited by 958
Insulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764
Dickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29715 · Cited by 642
“Both are recognized Hsp90 client proteins and have been implicated in tau phosphorylation (32, 33).”
BackgroundIs Alzheimer’s disease a type 3 diabetes? A critical appraisal
Kandimalla, R., Thirumala, V., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.018 · Cited by 621
Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans
Kullmann, S., Heni, M., Hallschmid, M., Fritsche, A., Preissl, H., & Häring, H.-U. (2016) · Physiological Reviews · doi:10.1152/physrev.00032.2015 · Cited by 622
Glycogen synthase kinase-3 signaling in Alzheimer's disease
Lauretti, E., Dincer, O., & Praticò, D. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118664 · Cited by 615
The role of insulin receptor signaling in the brain
Plum, L., Schubert, M., & Brüning, J. C. (2005) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2005.01.008 · Cited by 604
Type 2 diabetes mellitus, cognitive impairment and dementia
Stewart, R., & Liolitsa, D. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00027.x · Cited by 562
de la Monte, S. M., & Wands, J. R. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7106 · Cited by 553
Cholinergic Deficiency Hypothesis in Delirium: A Synthesis of Current Evidence
Hshieh, T. T., Fong, T. G., Marcantonio, E. R., & Inouye, S. K. (2008) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/63.7.764 · Cited by 553
Brain Insulin Receptors and Spatial Memory
Zhao, W., Chen, H., Xu, H., Moore, E., Meiri, N., Quon, M. J., & Alkon, D. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34893 · Cited by 528
Lannert, H., & Hoyer, S. (1998) · Behavioral Neuroscience · doi:10.1037//0735-7044.112.5.1199 · Cited by 525
Verdile, G., Keane, K. N., Cruzat, V. F., Medic, S., Sabale, M., Rowles, J., Wijesekara, N., Martins, R. N., Fraser, P. E., & Newsholme, P. (2015) · Mediators of Inflammation · doi:10.1155/2015/105828 · Cited by 495
Gasparini, L., Gouras, G. K., Wang, R., Gross, R. S., Beal, M. F., Greengard, P., & Xu, H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02561.2001 · Cited by 492
The Insulin-Like Growth Factor System and Its Pleiotropic Functions in Brain
Russo, V. C., Gluckman, P. D., Feldman, E. L., & Werther, G. A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0024 · Cited by 492
How does diabetes accelerate Alzheimer disease pathology?
Sims-Robinson, C., Kim, B., Rosko, A., & Feldman, E. L. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.130 · Cited by 492
Insulin Receptor Substrate-2 Deficiency Impairs Brain Growth and Promotes Tau Phosphorylation
Schubert, M., Brazil, D. P., Burks, D. J., Kushner, J. A., Ye, J., Flint, C. L., Farhang-Fallah, J., Dikkes, P., Warot, X. M., Rio, C., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-18-07084.2003 · Cited by 488
Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer’s disease
Lester-Coll, N., Rivera, E. J., Soscia, S. J., Doiron, K., Wands, J. R., & de la Monte, S. M. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9102 · Cited by 467
Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3
Hong, M., Chen, D. C. R., Klein, P. S., & Lee, V. M.-Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25326 · Cited by 469
Self-citationGriffin, R. J., Moloney, A., Kelliher, M., Johnston, J. A., Ravid, R., Dockery, P., O'Connor, R., & O'Neill, C. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02949.x · Cited by 459
Tau phosphorylation: physiological and pathological consequences
Stoothoff, W. H., & Johnson, G. V. W. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.06.017 · Cited by 442
Glucose metabolism and insulin receptor signal transduction in Alzheimer disease
Hoyer, S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.049 · Cited by 434
Microtubules and signal transduction
Gundersen, G. G., & Cook, T. A. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80010-6 · Cited by 407
Altered Insulin Signaling in Alzheimer’s Disease Brain – Special Emphasis on PI3K-Akt Pathway
Gabbouj, S., Ryhänen, S., Marttinen, M., Wittrahm, R., Takalo, M., Kemppainen, S., Martiskainen, H., Tanila, H., Haapasalo, A., Hiltunen, M., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00629 · Cited by 401
Insulin resistance and Alzheimer's disease
De La Monte, S. M. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.8.475 · Cited by 392
“AβPP-Aβ(1-40) and AβPPAβ (1-42), the main physiological C-terminal cleavage products of AβPP, inhibit insulin binding and insulin receptor auto-phosphorylation by reducing affinity of insulin binding to its own receptor (29).”
BackgroundCyclic AMP Promotes Neuronal Survival by Phosphorylation of Glycogen Synthase Kinase 3β
Li, M., Wang, X., Meintzer, M. K., Laessig, T., Birnbaum, M. J., & Heidenreich, K. A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.24.9356-9363.2000 · Cited by 363
Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease
Frisardi, V., Solfrizzi, V., Seripa, D., Capurso, C., Santamato, A., Sancarlo, D., Vendemiale, G., Pilotto, A., & Panza, F. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.04.007 · Cited by 357
Tramutola, A., Triplett, J. C., Di Domenico, F., Niedowicz, D. M., Murphy, M. P., Coccia, R., Perluigi, M., & Butterfield, D. A. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13037 · Cited by 347
HIV-1 infection and AIDS: consequences for the central nervous system
Kaul, M., Zheng, J., Okamoto, S., Gendelman, H. E., & Lipton, S. A. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401623 · Cited by 347
Michailidis, M., Moraitou, D., Tata, D. A., Kalinderi, K., Papamitsou, T., & Papaliagkas, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052687 · Cited by 330
“GSK-3β has been shown to lead to tau protein phosphorylation; it has also been shown that insulin secretion and action reduce GSK-3β activity by activating the PI3 kinase signaling pathway [73].”
BackgroundAbbott, M.-A., Wells, D. G., & Fallon, J. R. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-17-07300.1999 · Cited by 327
GBP, an Inhibitor of GSK-3, Is Implicated in Xenopus Development and Oncogenesis
Yost, C., Farr, G. H., Pierce, S. B., Ferkey, D. M., Chen, M. M., & Kimelman, D. (1998) · Cell · doi:10.1016/s0092-8674(00)81208-8 · Cited by 328
de la Monte, S. M., Tong, M., Lester-Coll, N., Plater, Jr., & Wands, J. R. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-10113 · Cited by 325
Signaling by insulin-like growth factor 1 in brain
Bondy, C. A., & Cheng, C. M. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.042 · Cited by 323
Insulin in Central Nervous System: More than Just a Peripheral Hormone
Duarte, A. I., Moreira, P. I., & Oliveira, C. R. (2012) · Journal of Aging Research · doi:10.1155/2012/384017 · Cited by 322
Spittaels, K., Van den Haute, C., Van Dorpe, J., Geerts, H., Mercken, M., Bruynseels, K., Lasrado, R., Vandezande, K., Laenen, I., Boon, T., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006219200 · Cited by 316
Does insulin dysfunction play a role in Alzheimer's disease?
Gasparini, L. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02037-0 · Cited by 314
Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P.-O., Bezard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 309
Aberrant insulin signaling in Alzheimer's disease: current knowledge
Bedse, G., Di Domenico, F., Serviddio, G., & Cassano, T. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00204 · Cited by 292
Jolivalt, C. G., Lee, C. A., Beiswenger, K. K., Smith, J. L., Orlov, M., Torrance, M. A., & Masliah, E. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21787 · Cited by 287
Therapy insight, type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease
Haan, M. N. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0124 · Cited by 284
Bosco, D., Fava, A., Plastino, M., Montalcini, T., & Pujia, A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01318.x · Cited by 283
Diabetes mellitus and dementia
Pasquier, F., Boulogne, A., Leys, D., & Fontaine, P. (2006) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70298-7 · Cited by 276
Potential roles of insulin and IGF-1 in Alzheimer's disease
Gasparini, L., & Xu, H. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00163-2 · Cited by 276
Areosa Sastre, A., Vernooij, R. W., González-Colaço Harmand, M., & Martínez, G. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003804.pub2 · Cited by 272
Lithium protects cultured neurons against β‐amyloid‐induced neurodegeneration
Alvarez, G., Muñoz-Montaño, J. R., Satrústegui, J., Avila, J., Bogónez, E., & Dı́az-Nido, J. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00685-7 · Cited by 270
Glycogen Synthase Kinase 3β Phosphorylates Tau at Both Primed and Unprimed Sites
Cho, J.-H., & Johnson, G. V. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m206236200 · Cited by 266
High-dose estradiol improves cognition for women with AD: Results of a randomized study
Asthana, S., Baker, L. D., Craft, S., Stanczyk, F. Z., Veith, R. C., Raskind, M. A., & Plymate, S. R. (2001) · Neurology · doi:10.1212/wnl.57.4.605 · Cited by 266
Hoyer, S. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050067 · Cited by 265
Alzheimer-Like Changes in Rat Models of Spontaneous Diabetes
Li, Z.-G., Zhang, W., & Sima, A. A. F. (2007) · Diabetes · doi:10.2337/db07-0171 · Cited by 265
Planel, E., Miyasaka, T., Launey, T., Chui, D.-H., Tanemura, K., Sato, S., Murayama, O., Ishiguro, K., Tatebayashi, Y., & Takashima, A. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5561-03.2004 · Cited by 261
Diabetes and Alzheimer’s disease crosstalk
Baglietto-Vargas, D., Shi, J., Yaeger, D. M., Ager, R., & LaFerla, F. M. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.005 · Cited by 256
Insulin Resistance and Alzheimers Disease: Molecular Links & Clinical Implications
Neumann, K., Rojo, L., Navarrete, L., Farias, G., Reyes, P., & Maccioni, R. (2008) · Current Alzheimer Research · doi:10.2174/156720508785908919 · Cited by 236
Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?
Correia, S. C., Santos, R. X., Perry, G., Zhu, X., Moreira, P. I., & Smith, M. A. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.01.001 · Cited by 212
Glucose Transporters in Brain: In Health and in Alzheimer’s Disease
Szablewski, L. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160841 · Cited by 211
“Insulin stimulation reduces tau protein phosphorylation and promotes its binding to microtubules [128] and regulates soluble A (cid:2) PP release [140].”
Association of type 2 diabetes with brain atrophy and cognitive impairment
Roberts, R. O., Knopman, D. S., Przybelski, S. A., Mielke, M. M., Kantarci, K., Preboske, G. M., Senjem, M. L., Pankratz, V. S., Geda, Y. E., Boeve, B. F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000269 · Cited by 211
Insulin-like growth factor 1 regulates developing brain glucose metabolism
Cheng, C. M., Reinhardt, R. R., Lee, W.-H., Joncas, G., Patel, S. C., & Bondy, C. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170008497 · Cited by 204
Choroid Plexus Megalin Is Involved in Neuroprotection by Serum Insulin-Like Growth Factor I
Carro, E., Spuch, C., Trejo, J. L., Antequera, D., & Torres-Aleman, I. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2909-05.2005 · Cited by 177
Effect of Intranasal Insulin on Cognitive Function: A Systematic Review
Shemesh, E., Rudich, A., Harman-Boehm, I., & Cukierman-Yaffe, T. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1802 · Cited by 162
Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain
Perluigi, M., Pupo, G., Tramutola, A., Cini, C., Coccia, R., Barone, E., Head, E., Butterfield, D. A., & Di Domenico, F. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.007 · Cited by 155
Insulin metabolism in Alzheimer’s disease differs according to apolipoprotein E genotype and gender
Craft, S., Asthana, S., Schellenberg, G., Cherrier, M., Baker, L. D., Newcomer, J., Plymate, S., Latendresse, S., Petrova, A., Raskind, M., et al. (1999) · Neuroendocrinology · doi:10.1159/000054469 · Cited by 154
Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus
Moroz, N., Tong, M., Longato, L., Xu, H., & de la Monte, S. M. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15103 · Cited by 151
Fasting insulin and incident dementia in an elderly population of Japanese-American men
Peila, R., Rodriguez, B. L., White, L. R., & Launer, L. J. (2004) · Neurology · doi:10.1212/01.wnl.0000129989.28404.9b · Cited by 152
Hartigan, J. A., & Johnson, G. V. W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.30.21395 · Cited by 141
Baker, L. D., Barsness, S. M., Borson, S., Merriam, G. R., Friedman, S. D., Craft, S., & Vitiello, M. V. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1970 · Cited by 138
“Herein, we present the results of our 5-month randomized controlled trial of GHRH administration, building on our previous work and on the reports by others linking lower IGF-1 levels with poorer cognitive performance.11,13,32-34 We expanded the sample to include adults with amnestic MCI presumably in the early stage…”
BackgroundTau and Axonopathy in Neurodegenerative Disorders
Higuchi, M., Lee, V. M.-Y., & Trojanowski, J. Q. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:2:2:131 · Cited by 134
Self-citationMetformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy
Barini, E., Antico, O., Zhao, Y., Asta, F., Tucci, V., Catelani, T., Marotta, R., Xu, H., & Gasparini, L. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0082-7 · Cited by 126
Glycogen synthase kinase 3β is tyrosine phosphorylated by PYK2
Hartigan, J. A., Xiong, W.-C., & Johnson, G. V. W. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4986 · Cited by 117
Streptozotocin-induced sporadic Alzheimer’s disease: Selection of appropriate dose
Mehla, J., Pahuja, M., & Gupta, Y. K. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120958 · Cited by 113
“It is well reported in previous studies that ICV injected STZ causes cholinergic dysfunction, hyperphosphorylation of tau protein, insulin receptor dysfunction, oxidative stress, mitochondrial dysfunction, impaired energy metabolism and activation of proapoptotic signaling pathways, which are similar to those observed…”
The role of tau in Alzheimer's disease
Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00002-0 · Cited by 85
Self-citationIron Deposition Leads to Hyperphosphorylation of Tau and Disruption of Insulin Signaling
Wan, W., Cao, L., Kalionis, B., Murthi, P., Xia, S., & Guan, Y. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00607 · Cited by 84
Isik, A. T., Celik, T., Ulusoy, G., Ongoru, O., Elibol, B., Doruk, H., Bozoglu, E., Kayir, H., Mas, M. R., & Akman, S. (2009) · AGE · doi:10.1007/s11357-008-9078-8 · Cited by 76
Piccialli, I., Tedeschi, V., Caputo, L., D’Errico, S., Ciccone, R., De Feo, V., Secondo, A., & Pannaccione, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876614 · Cited by 73
Early developmental expression of two insulins in zebrafish (Danio rerio)
Papasani, M. R., Robison, B. D., Hardy, R. W., & Hill, R. A. (2006) · Physiological Genomics · doi:10.1152/physiolgenomics.00012.2006 · Cited by 66
Santos, R. X., Correia, S. C., Alves, M. G., Oliveira, P. F., Cardoso, S., Carvalho, C., Duarte, A. I., Santos, M. S., & Moreira, P. I. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.011 · Cited by 61
Johnson, G. V. W., & Bailey, C. D. C. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4505 · Cited by 61
Rhein, V., & Eckert, A. (2007) · Archives of Physiology and Biochemistry · doi:10.1080/13813450701572288 · Cited by 56
Ida, S., Nakai, M., Ito, S., Ishihara, Y., Imataka, K., Uchida, A., Monguchi, K., Kaneko, R., Fujiwara, R., Takahashi, H., et al. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.06.012 · Cited by 55
Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease
Reich, N., & Hölscher, C. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.614828 · Cited by 48
“, 2011), hence the loss of insulin signaling initiates Tau hyperphosphorylation and aggregation in AD (Hong and Lee, 1997; Schubert et al., 2003, 2004).”
BackgroundZhang, Y., Yin, F., Liu, J., & Liu, Z. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12673 · Cited by 34
Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?
McIntyre, R. S., Soczynska, J. K., Woldeyohannes, H. O., Lewis, G. F., Leiter, L. A., MacQueen, G. M., Miranda, A., Fulgosi, D., Konarski, J. Z., & Kennedy, S. H. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.11.1615 · Cited by 32
“Insulin has a direct effect on the proapoptotic machinery with resultant accumulation of pathogenic tau protein [61,67-70] .”
Background
Metadata
- Authors
- Hong, M., & Lee, V. M.-Y.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1997-08
- Volume
- 272
- Issue
- 31
- Pages
- 19547-19553
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2031472414
- Cited by
- 522
- References
- 61
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.